Impact of Bispecific Antibodies on Multiple Myeloma Treatment

Now Viewing

EP: 1.Impact of Bispecific Antibodies on Multiple Myeloma Treatment

EP: 2.Key Considerations in Treatment Selection for Patients With Multiple Myeloma

EP: 3.Monitoring and Treating Adverse Events in Patients Receiving Treatment With a Bispecific Antibody

EP: 4.Risk Evaluation Mitigation Strategy (REMS) Program Requirements for Bispecific Antibodies

EP: 5.The Importance of Engaging Stakeholders When Implementing Bispecific Antibodies

EP: 6.Stakeholder Perspective: Step-Up Dosing for Bispecific Antibodies in Multiple Myeloma

EP: 7.Overcoming Challenges Related to Bispecific Antibody Adoption in Multiple Myeloma

EP: 8.Final Thoughts on Operationalization of Bispecific Antibodies for Multiple Myeloma

EP: 9.Step-Up Dosing of Bispecifics in the Outpatient Setting for Patients with Multiple Myeloma

EP: 10.Multidisciplinary Team Approach to Adverse Effect Monitoring for Bispecifics in MM

EP: 11.Complying with REMS Training and Documentation Requirements

EP: 12.Pharmacist Role in Addressing Operational Challenges of Bispecifics in MM

EP: 13.Unmet Needs in Multiple Myeloma Care

EP: 14.Treatment Sequencing and Combination Therapies for MM

EP: 15.Key Takeaways Regarding Operationalizing Bispecific Antibodies for MM

EP: 16.Impact of the Introduction of Bispecifics on the Management of Multiple Myeloma

EP: 17.Key Results From the MajesTEC-1, MonumenTAL-1, and MagnetisMM-3 Trials

EP: 18.Identifying Patients Who Are Candidates for Bispecifics and Referring Patients for Care

EP: 19.Collaborating with Other Care Providers to Optimize Outcomes for Patients Receiving Bispecifics

EP: 20.Considerations for Maintenance Therapy in the Community Oncology Setting

EP: 21.Team Approach to Meeting REMS Program Requirements

EP: 22.Role of Pharmacists in Operationalizing Bispecific Antibodies

EP: 23.Bispecific Antibodies Versus CAR T-Cell Therapy for RRMM in the Community Oncology Setting

EP: 24.Unmet Needs in Relapsed or Refractory Multiple Myeloma

This video discusses the evolving landscape of bispecific antibody therapy for relapsed/refractory multiple myeloma (RRMM). The specialists are Ryan Haumschild, PharmD, MS, MBA; hematologist Matthew Pianko, MD; and Anthony Perissinotti, PharmD, BCOP.

Pianko explains that the recent FDA approvals of the bispecific antibodies teclistamab, elranatamab, and talquetamab and have dramatically impacted RRMM treatment. These new, highly effective immunotherapies provide options for RRMM patients who previously had poor choices after their fifth line of therapy. The efficacy and safety balance of bispecific antibodies enables their paradigm-shifting use earlier in myeloma treatment lines in coming years.

Haumschild notes that just 5 years ago, there were limited RRMM options beyond proteasome inhibitors and immunomodulators. Since then, the first B-cell maturation antigen antibody-drug conjugate, chimeric antigen receptor T-cell therapies, and now bispecific antibodies with multiple mechanisms of action have become available. This enables durable response potential across multiple myeloma treatment lines.

In summary, the specialists emphasize how bispecific antibodies are improving outlooks for RRMM patients by providing new, effective treatment options not previously available to this difficult-to-treat population.

Video synopsis is AI-generated and reviewed by Pharmacy Times® editorial staff.